Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.55, $0.02 better than the analyst estimate of $0.53. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.93 billion.

GUIDANCE:

Teva Pharma sees FY2020 EPS of $2.30-$2.55, versus the consensus of $2.50. Teva Pharma sees FY2020 revenue of $16.6-17 billion, versus the consensus of $16.8 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.